Open access
Aug 2026
SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model
In vivo proof-of-concept for SNCA-targeted transcriptional repression therapy in a PD-mouse model is provided and its further preclinical development toward investigational new drug enablement is supported.
Bernadette O'Donovan, Joseph E. Rittiner, Suraj Upadhya et al.
· Neurotherapeutics · 0 citations